Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.

× No keyword cloud information.

13 in total

1. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Authors: Susan Halabi; Chen-Yen Lin; W Kevin Kelly; Karim S Fizazi; Judd W Moul; Ellen B Kaplan; Michael J Morris; Eric J Small
Journal: J Clin Oncol Date: 2014-01-21 Impact factor: 44.544

2. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228.

Authors: Stephen J Freedland; William J Aronson
Journal: Urol Oncol Date: 2017-06-13 Impact factor: 3.498

3. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Authors: Ugo De Giorgi; Paola Caroli; Emanuela Scarpi; Vincenza Conteduca; Salvatore Luca Burgio; Cecilia Menna; Andrea Moretti; Riccardo Galassi; Lorena Rossi; Dino Amadori; Giovanni Paganelli; Federica Matteucci
Journal: Eur J Nucl Med Mol Imaging Date: 2015-03-26 Impact factor: 9.236

Review 4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal: Eur Urol Date: 2013-11-12 Impact factor: 20.096

5. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.

Authors: Salvatore L Burgio; Vincenza Conteduca; Britt Rudnas; Francesco Carrozza; Enrico Campadelli; Emanuela Bianchi; Paolo Fabbri; Marco Montanari; Elisa Carretta; Cecilia Menna; Ugo De Giorgi
Journal: Clin Genitourin Cancer Date: 2014-06-12 Impact factor: 2.872

6. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.

Authors: Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Riccardo Schiavina; Riccardo Renzi; Marco Borghesi; Piergiorgio Di Tullio; Eugenio Brunocilla; Andrea Ardizzoni; Stefano Fanti
Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-01 Impact factor: 9.236

7. Molecular determinants of resistance to antiandrogen therapy.

Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440

8. Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.

Authors: Francesca Maines; Orazio Caffo; Davide Donner; Isabella Sperduti; Emilio Bria; Antonello Veccia; Franca Chierichetti; Giampaolo Tortora; Enzo Galligioni
Journal: Future Oncol Date: 2016-01-15 Impact factor: 3.404

9. Prospective evaluation of [¹¹C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.

Authors: Sarah M Schwarzenböck; Matthias Eiber; Günther Kundt; Margitta Retz; Monique Sakretz; Jens Kurth; Uwe Treiber; Roman Nawroth; Ernst J Rummeny; Jürgen E Gschwend; Markus Schwaiger; Mark Thalgott; Bernd J Krause
Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-17 Impact factor: 9.236

PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer.